Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy, is poised to become the top-selling drug franchise globally. However, competition from Eli Lilly's Zepbound and other emerging treatments could challenge its dominance. Meanwhile, Smoothie King has launched a new menu catering to users of GLP-1 medications, reflecting the growing popularity of these drugs among Americans.